Institutional members access full text with Ovid®

Share this article on:

A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease

Ramírez Gómez, Carolina Candelaria MD; Serrano Dueñas, Marcos MD; Bernal, Oscar MD; Araoz, Natalia MD; Sáenz Farret, Michel MD; Aldinio, Victoria MD; Montilla, Verónica MD; Micheli, Federico MD, PhD

doi: 10.1097/WNF.0000000000000202
Original Articles

Objectives Impulse control disorder (ICD) is a common adverse effect in patients with Parkinson disease who receive dopamine agonists; however, other factors are involved in its manifestations. To study the frequency and factors involved in the development of this adverse effect in a Latin American population, we conducted a cross-sectional multicenter study.

Methods Two hundred fifty-five patients in 3 Latin American centers were evaluated by examination and application of scales (Unified Parkinson’s Disease Rating Scale, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale, Hoehn and Yahr, Clinical Impression of Severity Index for Parkinson’s Disease).

Results Of the patients, 27.4% had ICD, most of whom were on dopamine agonists. Other associated risk factors included a younger age at onset of Parkinson disease, moderate symptoms, a shorter evolution of the clinical manifestations, rapid eye movement (REM) sleep disorder behavior, and the consumption of tea, mate, and alcohol.

Conclusions The frequency of ICD is higher in Latin America than in Anglo-Saxon populations. Consuming tea and mate, in addition to the use of dopamine agonists, is a factor that may demonstrate a genetic link that predisposes patients to the establishment of an ICD.

*Parkinson’s Disease and Movement Disorder Unit, Hospital de Clínicas “José de San Martín,” School of Medicine, University of Buenos Aires, Buenos Aires, Argentina; †School of Medicine, Pontifical Catholic University of Ecuador, and Neurological Unit, “Carlos Andrade Marín” Hospital, Quito, Ecuador; and ‡Nueva Granada Military University, Military Hospital, Santa Fe de Bogotá Foundation, Bogotá, Colombia.

Address correspondence and reprint requests to Federico Micheli, MD, PhD, Juncal 1695 5J, 1062, C.A.B.A., Argentina; E-mail: fmicheli@fibertel.com.ar

Conflicts of Interest and Source of Funding: F.M. received honoraria from Eli Lilly, Allergan, Boehriger Ingelheim, Novartis, UCB, Merz, and Viguera. The other authors have no conflicts of interest to declare.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.